Platform

 

UNION works with small molecules that have broadly applicable mode of action and demonstrated safety.

UNION currently works with two lead molecules with broad applicability across therapeutic areas:

  • Orismilast is a next-generation PDE4 inhibitor with demonstrated broad anti-inflammatory properties selected on the basis of an attractive therapeutic window (i.e., the combination of improved efficacy and tolerability)
     
  • Niclosamide is a broad spectrum anti-infective that modulates electrochemical gradients across biological membranes. The potent activity across a range of pathogenic viruses and bacteria supports wide applicability across respiratory infections and beyond

It is a part of UNION’s strategy to in-license molecules for further development. UNION expects to continue to source additional new small molecules with well characterised modes of action and safety profile that can be developed broadly within respiratory infections and immunology.